English

• 22 May, 2026
  Spago Nanomedical resolves on a rights issue of approximately SEK 16 million
• 19 May, 2026
  Spago Nanomedical publishes the annual report for 2025
• 18 May, 2026
  Spago Nanomedical presents Tumorad® clinical data at the international ANZSNM 2026 conference
• 11 May, 2026
  NOTICE TO ANNUAL GENERAL MEETING OF SPAGO NANOMEDICAL AB (PUBL)
• 7 May, 2026
  Spago Nanomedical interim report January-March 2026
• 6 May, 2026
  Spago Nanomedical’s phase I/IIa study Tumorad-01 meets a primary endpoint and provides further visible tumor uptake
• 24 Mar, 2026
  Spago Nanomedical’s abstract on Tumorad® accepted for presentation at radiopharma conference
• 17 Mar, 2026
  Spago Nanomedical continues recruitment in the phase I/IIa Tumorad-01 study following positive DMC recommendation
• 10 Mar, 2026
  Spago Nanomedical strengthens CMC and supply capabilities to support next phase of Tumorad development
• 5 Feb, 2026
  Spago Nanomedical year-end report January-December, 2025